Mankind Pharma’s Board of Directors has approved the unaudited standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. The decision was made at a board meeting held on February 3, 2026. Joint Statutory Auditors have issued an unmodified opinion on these results. The details of financial performance are included in the report.
Q3 Financial Results Approved
Mankind Pharma has announced the approval of its unaudited financial results for Q3 2026, which corresponds to the quarter ended December 31, 2025. This includes both standalone and consolidated figures. The approval was formalized during a board meeting on February 3, 2026.
Auditor’s Review
The financial results have undergone a limited review by the Joint Statutory Auditors, M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., Chartered Accountants. The auditors have issued an unmodified opinion on the company’s financial results.
Standalone Financial Performance Highlights
Key figures from the unaudited standalone results include:
- Revenue from operations: ₹2,632.68 crore
- Profit after tax: ₹449.47 crore
- Total comprehensive income: ₹452.53 crore
- Basic EPS from continuing operations: ₹10.89
Consolidated Financial Performance Highlights
Key figures from the unaudited consolidated results include:
- Revenue from operations: ₹3,567.20 crore
- Profit after tax: ₹413.88 crore
- Total comprehensive income: ₹419.83 crore
- Basic EPS from continuing operations: ₹9.90
Debt-Equity Ratio
The debt-equity ratio is reported as 0.40. Further details about other financial ratios are available in the detailed financial statements.
Tax Proceedings
The company has disclosed ongoing income tax proceedings. Appeals against these proceedings are currently pending with appellate tax authorities.
Business Updates
The Over the Counter (OTC) business of the company has been transferred to Mankind Consumer Products Private Limited on September 30, 2024.
Source: BSE
